“This study using ‘Western’ type high-fat, diet fed obese mice, suggests that medications with the actions of LSF could reduce inflammation and insulin resistance associated with central obesity – therefore providing a novel opportunity to treat heart disease and prevent type 2 diabetes development... [PDF] DiaKine's Press Release -
Blog Archive
-
▼
2008
(55)
-
▼
April
(9)
- Orexigen Therapeutics : Completion of Enrollment ...
- Znomics : Drug Discovery Program in Obesity Using ...
- Pacific Biometrics : Research Contracts as Part of...
- University of Virginia : DiaKine's Lisofylline Red...
- SCN, Scandinavian Clinical Nutrition : diagnosis a...
- Memory Pharmaceuticals : Advance Development and C...
- Genaera Corporation : MSI-1436 Data Presented at S...
- Merck : Phase III Data Showed Taranabant, its Inv...
- VIVUS : Enrollment in Phase 3 EQUIP (OB-302) Tria
-
▼
April
(9)
Friday, April 18, 2008
University of Virginia : DiaKine's Lisofylline Reduces Obesity-Related Inflammation and Insulin Resistance
April 16, 2008 - -DiaKine Therapeutics announced that its developmental drug Lisofylline (LSF), significantly reduced indicators of inflammation in visceral fat tissue that are predictive of heart disease and diabetes risk, according to results of a pre-clinical study presented at the Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2008.